Search

The main results of a medical-sociological study aimed at the evaluation of the level of satisfaction with treatment in patients with primary progressive multiple sclerosis (PPMS) are presented. The survey was conducted in 19 regions of the Russian Federation and involved 437 patients with confirmed diagnosis of PPMS and 80 neurologists specialized in multiple sclerosis. The research was carried out by the All-Russian Public Organization of Disabled People with Multiple Sclerosis with the participation of the Russian Committee for Treatment and Research in Multiple Sclerosis. This is the first medical-sociological study in the Russian Federation involving patients with PPMS and neurologists. The study revealed typical medical and social problems patients with PPMS faced. A significant decrease in quality-of-life of PPMS patients was shown.Представлены основные результаты медико-социологического исследования, проведенного с целью изучения уровня удовлетворенности терапией пациентов с первично-прогрессирующим рассеянным склерозом (ППРС). В опросе, проведенном в 19 регионах Российской Федерации, приняли участие 437 пациентов с установленным диагнозом ППРС и 80 неврологов, специализирующихся в области данного заболевания. Исследовательский проект был осуществлен Общероссийской общественной организацией инвалидов - больных рассеянным склерозом (ОООИБРС) при научном участии Российского комитета исследователей рассеянного склероза (РОКИРС). Это первый опыт проведения медико-социологического исследования на территории РФ, охватывающий и больных ППРС, и неврологов. Выявлены типичные медицинские и социальные проблемы, с которыми сталкиваются пациенты с ППРС, отмечено существенное снижение качества жизни данной группы больных.

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. Nowadays some disease-modifying drugs (DMD) in the Russian Federation (RF) are biosimilars. Their full spectrum of tolerability and efficacy is to be determined. Here we present results of two retrospective-prospective studies on efficacy and safety of a biosimilar interferon beta-1a (genfaxon) in treatment of MS in the RF.determination of safety and efficacy profile of genfaxon in a routine neurological practice in the RF.Trials were performed in 18 MS centers in the RF. A total of 649 patients aged from 18 to 68 years with the EDSS score no more than 6.0 were treated with genfaxon for 12 months. The first group was comprised of 'naïve' patients without previous history of DMD administration. There were patients in the second group which have already received some of DMD. Statistical analysis was performed with the help of significance criteria (χ-square), t-criteria of Student for analysis of independent samplings.There were no serious adverse events during the period of the study. "Naïve" patients had significantly lower number of adverse events, than patients with previous history of DMD usage. Efficacy results were comparable with results published for the Rebif.Data, received from the studies show equal efficacy and tolerability of genfaxon compared with original DMD Rebif.